BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kobayashi S, Nagano H, Tomokuni A, Gotoh K, Sakai D, Hatano E, Seo S, Terajima H, Uchida Y, Ajiki T, Satake H, Kamei K, Tohyama T, Hirose T, Ikai I, Morita S, Ioka T. A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery 2019;270:230-7. [DOI: 10.1097/sla.0000000000002865] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Kosaka H, Kaibori M, Matsui K, Ishizaki M, Matsushima H, Sekimoto M. Investigation of a Tumor Location-Specific Therapeutic Strategy for Intrahepatic Cholangiocarcinoma. Asian Pac J Cancer Prev 2021;22:1485-93. [PMID: 34048177 DOI: 10.31557/APJCP.2021.22.5.1485] [Reference Citation Analysis]
2 Luvira V, Satitkarnmanee E, Pugkhem A, Kietpeerakool C, Lumbiganon P, Pattanittum P. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma. Cochrane Database Syst Rev 2021;9:CD012814. [PMID: 34515993 DOI: 10.1002/14651858.CD012814.pub2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Zhang R, Puzzoni M, Mariani S, Zheng Y, Liscia N, Guo Y, Donisi C, Liu Y, Impera V, Fang W, Scartozzi M. Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. Cancer Sci 2021. [PMID: 34534382 DOI: 10.1111/cas.15139] [Reference Citation Analysis]
4 Mitsuura C, Okabe H, Yamashita YI, Itoyama R, Yamao T, Umezaki N, Miyata T, Higashi T, Yamamura K, Nakagawa S, Imai K, Hayashi H, Chikamoto A, Baba H. A case of chest wall recurrence of hilar cholangiocarcinoma 10 years after R1 surgery with positive ductal margin of carcinoma in situ. Int Cancer Conf J 2020;9:77-81. [PMID: 32257758 DOI: 10.1007/s13691-020-00400-y] [Reference Citation Analysis]
5 Kobayashi S, Wada H, Tomokuni A, Takahashi H, Gotoh K, Sakon M, Mori M, Doki Y, Eguchi H. Invasion category-oriented lymph node metastases of cholangiocarcinoma and the prognostic impact. Langenbecks Arch Surg 2020;405:989-98. [PMID: 32812064 DOI: 10.1007/s00423-020-01955-3] [Reference Citation Analysis]
6 Gao H, Tian T, Li S, Zhang Y, Fu X, Zheng X, Liu N, Jiang A, Ren M, Zhang X, Liang X, Ruan Z, Geng Z, Yao Y. Efficacy Analysis of Adjuvant Chemotherapy with Gemcitabine Plus Platinum or S-1 in Biliary Tract Carcinoma: A Multi-Center Retrospective Study. Cancer Manag Res 2021;13:889-98. [PMID: 33542660 DOI: 10.2147/CMAR.S290083] [Reference Citation Analysis]
7 Itano O, Takemura Y, Kishida N, Tamagawa E, Shinozaki H, Ikeda K, Urakami H, Ei S, Hayatsu S, Suzuki K, Sakuragawa T, Ishii M, Shito M, Aiura K, Fujisaki H, Takano K, Matsui J, Minagawa T, Shinoda M, Kitago M, Abe Y, Yagi H, Oshima G, Hori S, Kitagawa Y. A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01). BMC Cancer 2020;20:688. [PMID: 32703191 DOI: 10.1186/s12885-020-07185-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Matsukuma S, Tokumitsu Y, Shindo Y, Matsui H, Nagano H. Essential updates to the surgical treatment of biliary tract cancer. Ann Gastroenterol Surg 2019;3:378-89. [PMID: 31346577 DOI: 10.1002/ags3.12266] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
9 Akita M, Ajiki T, Ueno K, Tsugawa D, Hashimoto Y, Tanaka M, Kido M, Toyama H, Fukumoto T. Predictors of postoperative early recurrence of extrahepatic bile duct cancer. Surg Today 2020;50:344-51. [PMID: 31549244 DOI: 10.1007/s00595-019-01880-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 Ueno G, Iwagami Y, Kobayashi S, Mitsufuji S, Yamada D, Tomimaru Y, Akita H, Asaoka T, Noda T, Gotoh K, Mori M, Doki Y, Eguchi H. ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer. Ann Surg Oncol 2022. [PMID: 34994902 DOI: 10.1245/s10434-021-11152-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Oneda E, Abu Hilal M, Zaniboni A. Biliary Tract Cancer: Current Medical Treatment Strategies.Cancers (Basel). 2020;12. [PMID: 32423017 DOI: 10.3390/cancers12051237] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
12 Wang G, Wang Q, Fan X, Ding L, Dong L. The Significance of Adjuvant Therapy for Extrahepatic Cholangiocarcinoma After Surgery. Cancer Manag Res 2019;11:10871-82. [PMID: 31920396 DOI: 10.2147/CMAR.S224583] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]